Day: January 6, 2023

Nasdaq CopenhagenLondon Stock Exchange        Euronext DublinOther stakeholders Date 6 January 2023 Election of employee representatives to the bank’s board of directors An election of employee representatives for the bank’s board of directors has been completed today with the below result. The following will resign from the bank’s board of directors on 1 March 2023:Dan Junker Astrup, credit manager Arne Ugilt, credit consultant Gitte E. S. Vigsø, compliance officerThe following will continue/join as board members for a four-year term of office commencing 1 March 2023:Nanna Gammeljord Snogdal, team leader credit – new member Lisa Munkholm, personal customer adviser – new member Finn Aaen, business customer adviser – re-elected Martin Wilche, personal customer adviser – new memberYours sincerely Ringkjøbing Landbobank John...

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel genetically modified cell therapy in Crohn’s disease FLORHAM PARK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, announced today that its re-analysis of long term follow-up data from three legacy Phase 1, Phase 1b/2a and Phase 1b studies of its legacy placental-derived mesenchymal-like adherent stromal cell (MLASC) therapy in moderate-to-severe Crohn’s disease patients showed clinically meaningful and durable benefit for up to two years in the limited number of patients studied and warrants further investigation. These...

WARSAW, Ind., Jan. 06, 2023 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the establishment of its direct sales organization in Germany. OrthoPediatrics GmbH, commencing operations on January 1, 2023. OrthoPediatrics’ first direct international organization represents an expanding commitment to support pediatric orthopedics in international markets. “We are proud to establish OrthoPediatrics GmbH, which demonstrates our commitment to helping children across the globe,” said Mark Karshner, Senior Vice President of International Sales at OrthoPediatrics. “Having a direct organization in Germany will provide better insights on the unique needs of the pediatric community there, along with additional...

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT NEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA. The presentation is scheduled to take place on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research...

Figure 1 Plan Map of Surluga Deposit and Surrounding Shear ZonesFigure 2 Cross-Section of hole SD-22-396 with all gold assays above 0.5 gpt in the Hanging Wall and Footwall of the Surluga DepositTORONTO, Jan. 06, 2023 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”) is pleased to report results from its continuing exploration program. Hole SD-22-396 intersected significant mineralization in the Surluga North Vein Network above the Jubilee Shear Zone (hanging wall) of the current resources of the Wawa Gold Project. All reported drill widths are core length unless otherwise stated.High-grade mineralization in the Surluga North Vein Network extended laterally to the north by 115 mGold mineralization is associated with a network of multidirectional quartz-tourmaline veins The...

Baltman OÜ, a subsidiary of AS Baltika, and Kalaport OÜ entered into a compromise on January 5, 2023, which ended the legal dispute regarding the lease agreement for the Ivo Nikkolo store located at Suur-Karja 14 in Tallinn’s old town, which began in early 2021, by agreement between the parties. The content of the dispute is described in more detail in the stock exchange announcement published by AS Baltika on 09.02.2021. With the compromise, both Kalaport OÜ and Baltman OÜ mutually waived all claims and Baltman OÜ will continue to fulfill the lease agreement, taking into account the differences agreed in the compromise, from 01.02.2023. The parties have agreed that the terms of the compromise agreement are confidential. “We are glad that after a long legal dispute we reached a compromise that satisfies both parties, which gives...

Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024 Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancer Advance XMT-1660 and XMT-2056 Phase 1 trials Continue pursuing collaborations to maximize platform and pipeline potential Capital resources expected to support operating plan commitments into the second half of 2024CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones...

Panel of Proven Medical Device Entrepreneurs and Surgical Robotics Pioneers Will Share Their Personal Experiences of Taking Innovative New Technologies from Development to Commercialization Views on the Current and Future Endovascular Market will be Highlighted Webinar will be Held on Tuesday, January 10, 2023, at 2:00pm ET (11am PT) HINGHAM, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, announced that Joe Mullings, a renowned and successful leader in the medtech space, will moderate the next Access-Ability Live by MBOT webinar. The webinar episode will be held on Tuesday, January 10, 2023, at 2:00pm ET (11am PT), and will feature proven medical device entrepreneurs and recognized pioneers in the surgical...